ReviewCancer cell international2025
Exploring the role of long non-coding RNAs in renal cell carcinoma: insights into signaling pathways.
Review in Cancer cell international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Regulatory networks of non-coding RNAs in renal cell carcinogenesis and therapeutic intervention strategies.World journal of urology · 2026Review
- Functional roles and clinical implications of pseudogenes signatures as emerging biomarkers in cancer.Discover oncology · 2026Review
- Circadian rhythms and non-coding RNAs: mechanistic insights, clinical impact, and future opportunities for personalized medicine.Cancer cell international · 2026Review
- lncRNA HOTAIR in Cancer: Recent Advances and Critical Perspectives on Molecular Mechanisms.Cancer management and research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Renal cell carcinoma (RCC), the most common type of kidney cancer, is characterized by a poor prognosis due to its aggressive metastasis and resistance to treatment. Long non-coding RNAs (lncRNAs) have emerged as key regulators of RCC progression, influencing cellular processes such as proliferation, migration, invasion, and apoptosis. LncRNA biogenesis occurs through both canonical and non-canonical pathways, involving RNA Polymerase II-mediated transcription and alternative splicing. LncRNAs like HOTAIR, MALAT1, and GAS5 regulate critical signaling pathways, including the PI3K/AKT/mTOR axis, Wnt/β-catenin, and JAK/STAT, while others, such as RCAT1, DUXAP9, and Lnc-LSG1, modulate protein degradation, impacting tumor growth and metastasis. Additionally, lncRNAs like EGFR-AS1 and MALAT1 enhance the EGFR/AKT and VEGF/Akt pathways, driving RCC cell proliferation and migration. LncRNAs such as HOTAIR and TCL6 also promote epithelial-to-mesenchymal transition, contributing to tumor invasion and therapy resistance. Furthermore, lncRNAs regulate the p53 pathway, with some, like MEG3, acting as tumor suppressors, while others, like SNHG3, suppress p53 activity, accelerating RCC progression. These insights into lncRNA-mediated regulatory mechanisms provide promising therapeutic targets for RCC, suggesting that modulating specific lncRNAs or their associated pathways could offer innovative strategies for treatment and prognosis. This review presents a comprehensive analysis of the biogenesis, functions, and regulatory roles of lncRNAs in RCC, emphasizing their potential as diagnostic biomarkers and therapeutic targets to improve patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.